Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06784349 | ALN-APOC3 in Adult Participants With Dyslipidemia | PHASE1 | COMPLETED | 32 | — | — | Jan 27, 2025 | Feb 25, 2026 | Mar 16, 2026 | 1 | Moldova |
Part B Only
| Arm | Type | Description |
|---|---|---|
| ALN-APOC3 Ascending Cohorts | EXPERIMENTAL | Part A: Ascending Cohorts Randomized as described in the protocol May include optional cohorts |
| Placebo | PLACEBO_COMPARATOR | Part A and Part B: Randomized as described in the protocol |
| ALN-APOC3 low-dose | EXPERIMENTAL | Part B: Parallel Arm Randomized as described in the protocol |
| ALN-APOC3 medium-dose | EXPERIMENTAL | Part B: Parallel Arm Randomized as described in the protocol |
| ALN-APOC3 high-dose | EXPERIMENTAL | Part B: Parallel Arm Randomized as described in the protocol |
| Name | Type | Description |
|---|---|---|
| ALN-APOC3 | DRUG | Administered as per the protocol |
| Matching Placebo | DRUG | Administered as per the protocol |
Key Inclusion Criteria: 1. Judged by the investigator to be in good health based on medical history, physical examination, vital signs, Electrocardiograms (ECG's) and laboratory safety testing, as defined in the protocol 2. Participants can enter the study under one of the following options, as def...